Open AccessCorrection: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
Author(s) -
David M. Goldenberg,
Thomas M. Cardillo,
Serengulam V. Govindan,
Edmund A. Rossi,
Robert M. Sharkey
Publication year - 2020
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.27512
Subject(s) - antibody drug conjugate , medicine , conjugate , drug , cancer , antibody , brain cancer , pharmacology , oncology , cancer research , immunology , monoclonal antibody , mathematical analysis , mathematics